PharmaJet Announces Dr. Wouter Latour as the New Chief Executive Officer

PharmaJet®, a leader in enhancing the efficacy of injectable treatments through innovative technology, has announced the appointment of Wouter Latour, M.D., as its new Chief Executive Officer (CEO). In addition to his new role, Dr. Latour will also serve on PharmaJet’s board of directors. He succeeds Chris Cappello, who has been elected Vice-Chairman of the Board and will continue to play an active role in the company, focusing on strategic partnerships and supporting engineering and operations.

Dr. Latour brings over 30 years of experience in the industry to PharmaJet. He previously held the positions of CEO, President, Director, and Chairman of the Board at Vaxart, Inc., a clinical-stage biotechnology company specializing in oral recombinant vaccines. At Vaxart, he led the company through its initial public offering and advanced its pipeline of oral vaccine candidates targeting COVID-19, flu, norovirus, RSV, and HPV. His prior experience includes roles as CEO and Director at Trinity Biosystems and various global strategy and business development positions at Novartis Pharma and SmithKline Beecham Biologicals (now GSK Vaccines). He has also served as a strategic advisor for several mid-sized vaccine companies. Dr. Latour earned his Doctor of Medicine and Bachelor’s degrees from the University of Amsterdam, along with an MBA from Stanford University.

Gordon Clancy, Chairman of PharmaJet’s Board of Directors, expressed his confidence in Dr. Latour’s leadership, stating, “I am pleased to welcome Dr. Latour to PharmaJet and want to express my sincere confidence in him as he assumes the leadership of the Company. He is a proven biotechnology leader with a distinguished track record. The Board is confident that Wouter, together with the rest of the leadership team, will ensure strong execution of PharmaJet’s strategy to take advantage of the significant opportunities ahead. I also want to thank Chris Cappello for his invaluable contributions and his continued involvement with PharmaJet.”

In response to his appointment, Dr. Latour remarked, “This is an exciting time for PharmaJet, with tremendous prospects for growth and value creation. PharmaJet’s needle-free delivery system has shown enhanced effectiveness of nucleic acid vaccines and immunotherapies in numerous clinical and preclinical studies, providing a consistent and convenient method of delivery. The company has supplied over ten million syringes for large-scale polio eradication campaigns worldwide, and there are many other important therapeutic and vaccine applications for this technology. The recently announced strategic partnership with Scancell to develop a DNA vaccine for advanced melanoma using the PharmaJet delivery system exemplifies this potential. I am excited to join PharmaJet as we redefine the field of vaccine and therapeutic delivery.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter